一致Ｂ(200028):2022年半年度财务报告（英文版）
原标题:一致Ｂ:2022年半年度财务报告（英文版） Section X Financial Reporting Report of the Auditors Consolidated financial statements for the six months ended 30 June 2022 haven’t been audited. CHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. CONSOLIDATED BALANCE SHEET As at 30 June 2022 (Expressed in Renminbi Yuan) ASSETS Note V 30 June 2022 31 December 2021 Current assets Cash and bank balances 1 5,573,558,436.74 5,126,159,080.94 Notes receivable 2 634,263,913.50 680,196,380.57 Accounts receivable 3 19,066,131,973.48 15,964,603,345.91 Receivable financing 4 632,101,362.15 1,027,226,940.21 Advances to suppliers 5 384,131,138.51 520,930,545.31 Other receivables 6 624,860,452.74 718,089,129.10 Inventories 7 7,905,185,600.35 7,621,541,595.08 Contract Assets 8 28,169,112.57 29,061,159.52 Other current assets 9 119,092,606.71 160,607,355.66 Total current assets 34,967,494,596.75 31,848,415,532.30 Non-current assets Long-term equity investments 10 2,471,624,418.24 2,459,832,546.74 Other equity instrument investment 11 62,488,312.99 62,488,312.99 Other non-current financial 12 135,974,908.51 135,974,908.51 assets Investment properties 13 111,752,949.23 113,981,497.23 Fixed assets 14 835,798,833.09 868,626,258.43 Construction in progress 15 34,400,409.22 49,849,506.70 Right-of-use assets 16 2,628,310,313.99 2,575,240,340.00 Intangible assets 17 681,603,209.30 669,926,562.82 Goodwill 18 2,775,645,585.32 2,775,645,585.32 Long-term prepaid expenses 19 603,905,628.79 633,975,441.76 Deferred tax assets 20 184,991,505.33 129,740,169.77 Other non-current assets 21 474,990,153.81 459,985,769.24 Total non-current assets 11,001,486,227.82 10,935,266,899.51 Total assets 45,968,980,824.57 42,783,682,431.81 The accompanying notes form an integral part of these financial statements CHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. CONSOLIDATED BALANCE SHEET (Continued) As at 30 June 2022 (Expressed in Renminbi Yuan) LIABILITIES AND EQUITY Note V 30 June 2022 31 December 2021 Current liabilities Short-term borrowings 22 3,099,020,701.18 1,930,467,146.38 Notes payable 23 6,390,557,494.64 7,660,216,823.68 Accounts payable 24 11,329,463,911.07 9,057,718,968.14 Receipts in advance 25 18,140,667.15 19,289,567.44 Contract liabilities 26 446,665,021.01 431,303,231.37 Employee benefits payable 27 240,990,407.92 340,197,125.33 Tax payable 28 361,610,782.83 337,164,080.19 Other payables 29 2,248,815,946.18 1,714,746,986.46 Non-current liabilities due within one year 30 858,086,989.55 848,328,648.14 Other current liabilities 31 35,657,330.08 39,585,469.65 Total current liabilities 25,029,009,251.61 22,379,018,046.78 Non-current liabilities Long-term borrowings 32 62,633,794.44 71,637,173.89 Lease liabilities 33 1,391,474,612.88 1,375,427,877.28 Long-term payables 34 6,938,189.00 6,938,189.00 Long-term employee benefits payable 35 1,156,000.00 1,202,000.00 Deferred income 36 83,551,934.15 86,917,051.78 Deferred tax liabilities 20 168,518,914.25 175,948,328.93 Other non-current liabilities 37 695,542,286.70 664,381,065.65 Total non-current liabilities 2,409,815,731.42 2,382,451,686.53 Total liabilities 27,438,824,983.03 24,761,469,733.31 The accompanying notes form an integral part of these financial statements CHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. CONSOLIDATED BALANCE SHEET (Continued) As at 30 June 2022 (Expressed in Renminbi Yuan) LIABILITIES AND EQUITY Note V 30 June 2022 31 December 2021 Equity Share capital 38 428,126,983.00 428,126,983.00 Capital surplus 39 4,371,823,310.21 4,371,802,107.43 Other comprehensive income 40 21,870,425.19 21,874,198.36 Surplus reserve 41 214,063,491.50 214,063,491.50 Retained earnings 42 10,306,410,995.34 9,889,071,272.21 Total equity attributable to owners of the parent 15,342,295,205.24 14,924,938,052.50 Non-controlling interests 3,187,860,636.30 3,097,274,646.00 Total equity 18,530,155,841.54 18,022,212,698.50 Total liabilities and equity 42,783,682,431.81 45,968,980,824.57 The accompanying notes form an integral part of these financial statements The financial statements have been signed by: Legal representative: Financial controller: Head of Accounting Department: CHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. CONSOLIDATED INCOME STATEMENT (Continued) For the six months ended 30 June 2022 (Expressed in Renminbi Yuan) For the six months For the six months Note V ended 30 June 2022 ended 30 June 2021 Operating revenue 43 36,128,910,049.98 33,163,091,887.39 Less: Operating costs 43 31,939,019,815.60 29,216,837,201.07 Taxes and surcharges 44 95,897,105.33 75,989,854.58 Selling expenses 45 2,486,484,440.79 2,307,485,529.77 Administrative expenses 46 509,456,947.82 492,536,936.71 Finance costs 47 111,202,147.99 107,243,003.15 Incling: Interest expense 142,860,549.18 147,057,897.99 Interest income 34,626,066.94 38,758,729.78 Add: Other incomes 48 44,158,835.01 47,249,616.26 Investment income 49 48,938,159.28 156,587,066.32 Incling: Investment income from associates 98,868,662.09 157,696,397.81 Income from the derecognition of financial assets measured at amortised cost (49,930,502.81) (7,039,046.60) Credit impairment losses 50 (44,249,830.99) (28,664,985.44) Impairment losses 51 (6,498,659.33) (416,915.26) Gain on disposal of assets 52 3,192,821.77 (588,799.55) Operating profits 1,032,390,918.19 1,137,165,344.44 Add: Non-operating income 53 4,356,528.39 12,493,320.44 Less: Non-operating expenses 54 2,191,998.74 3,237,951.35 Total profit 1,034,555,447.84 1,146,420,713.53 55 239,786,355.07 238,426,259.04 Less: Income tax expenses Net profit 794,769,092.77 907,994,454.49 794,769,092.77 907,994,454.49 Net Profit from continuing operations 674,215,912.93 741,445,013.25 Net profit attributable to owners of the parent 120,553,179.84 166,549,441.24 Profit or loss of non-controlling interests CHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. CONSOLIDATED INCOME STATEMENT (Continued) For the six months ended 30 June 2022 (Expressed in Renminbi Yuan) For the six months ended For the six months ended Note V 30 June 2022 30 June 2021 Other comprehensive income, net of tax (3,773.17) 64,854.90 Other comprehensive income, net of tax, attributable to owners of the parent (3,773.17) 64,854.90 Other comprehensive income that will be reclassified to profit or loss (3,773.17) 64,854.90 Other comprehensive income using the equity method that will be reclassified to profit or loss (3,773.17) 64,854.90 Total comprehensive income 794,765,319.60 908,059,309.39 Incl: Total comprehensive income attributable to owners of the parent 674,212,139.76 741,509,868.15 Total comprehensive income 120,553,179.84 166,549,441.24 attributable to non-controlling interests Earnings per share Basic earnings per share 1.57 1.73 Diluted earnings per share 1.57 1.73 The accompanying notes form an integral part of these financial statementsCHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. CONSOLIDATED STATEMENT OF CHANGES IN EQUITY For the six months ended 30 June 2022 (Expressed in Renminbi Yuan) Attributable to owners of the parent Other For the six months ended 30 June 2022 comprehensive Non-controlling Share capital Capital surplus income Surplus reserves Retained earnings Subtotal interests Total equity I. Balance at end of prior year 428,126,983.00 4,371,802,107.43 21,874,198.36 214,063,491.50 9,889,071,272.21 14,924,938,052.50 3,097,274,646.00 18,022,212,698.50 428,126,983.00 4,371,802,107.43 21,874,198.36 214,063,491.50 9,889,071,272.21 14,924,938,052.50 3,097,274,646.00 18,022,212,698.50 II. Balance at beginning of year III. Changes for the year - 21,202.78 (3,773.17) - 417,339,723.13 417,357,152.74 90,585,990.30 507,943,143.04 (1) Total comprehensive income - - (3,773.17) - 674,215,912.93 674,212,139.76 120,553,179.84 794,765,319.60 (2) Owners’ contributions and reduction in capital - 21,202.78 - - - 21,202.78 2,700,000.00 2,721,202.78 1. Capital contributions by owners - - - - - 2,700,000.00 2,700,000.00 2. Others - 21,202.78 - - - 21,202.78 - 21,202.78 (3) Profit distribution - - - - (256,876,189.80) (256,876,189.80) (32,667,189.54) (289,543,379.34) (256,876,189.80) - - - - (256,876,189.80) (32,667,189.54) (289,543,379.34) 1.Distribution to equity owners 428,126,983.00 4,371,823,310.21 21,870,425.19 214,063,491.50 10,306,410,995.34 15,342,295,205.24 3,187,860,636.30 18,530,155,841.54 IV. Balance at end of year The accompanying notes form an integral part of these financial statementsCHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. CONSOLIDATED STATEMENT OF CHANGES IN EQUITY(Continued) For the six months ended 30 June 2022 (Expressed in Renminbi Yuan) Attributable to owners of the parent For the six months ended 30 June 2021 Other comprehensive Non-controlling Share capital Capital surplus income Surplus reserves Retained earnings Subtotal interests Total equity I. Balance at end of prior year 428,126,983.00 4,372,504,053.72 38,483,017.72 214,063,491.50 8,895,145,106.39 13,948,322,652.33 2,940,304,667.19 16,888,627,319.52 428,126,983.00 4,372,504,053.72 38,483,017.72 214,063,491.50 8,895,145,106.39 13,948,322,652.33 2,940,304,667.19 16,888,627,319.52 II. Balance at beginning of year III. Changes for the year - (460,868.29) 64,854.90 - 398,943,426.85 398,547,413.46 200,953,200.40 599,500,613.86 (1) Total comprehensive income - - 64,854.90 - 741,445,013.25 741,509,868.15 166,549,441.24 908,059,309.39 (2) Owners’ contributions and reduction in capital - (460,868.29) - - - (460,868.29) 58,773,146.38 58,312,278.09 1. Capital contributions by owners - - - - 15,680,000.00 15,680,000.00 2. Others - (460,868.29) - - - (460,868.29) 43,093,146.38 42,632,278.09 (3) Profit distribution - - - - (342,501,586.40) (342,501,586.40) (24,369,387.22) (366,870,973.62) - - - - (342,501,586.40) (342,501,586.40) (24,369,387.22) (366,870,973.62) 1.Distribution to equity owners 428,126,983.00 4,372,043,185.43 38,547,872.62 214,063,491.50 9,294,088,533.24 14,346,870,065.79 3,141,257,867.59 17,488,127,933.38 IV. Balance at end of year The accompanying notes form an integral part of these financial statements CHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. CONSOLIDATED STATEMENT OF CHANGES IN EQUITY(Continued) For the six months ended 30 June 2022 (Expressed in Renminbi Yuan) For the six months ended For the six months Note V 30 June 2022 ended 30 June 2021 1.CASH FLOWS FROM OPERATING ACTIVITIES Cash received from sales of good and the rendering of services 36,667,060,800.89 32,800,434,055.12 Receipts of taxes and surcharges refunds 7,086,718.77 9,380,253.27 Other cash receipts relating to operating activities 56 293,598,578.92 368,590,875.46 Total cash inflows from operating activities 36,967,746,098.58 33,178,405,183.85 Cash payments for goods and services 32,450,267,035.88 28,541,885,459.35 Cash payments to and on behalf of employees 1,814,169,897.07 1,708,255,657.44 Payments of all types of taxes and surcharges 950,560,063.59 766,110,586.13 Other cash payments relating to operating 56 711,085,042.87 932,780,197.36 activities Total cash outflows from operating activities 35,926,082,039.41 31,949,031,900.28 Net cash flows from operating activities 57 1,041,664,059.17 1,229,373,283.57 2.CASH FLOWS FROM INVESTING ACTIVITIES Cash receipts from returns of investments - 2,997,441.73 Cash receipts from returns on investments 70,380,000.00 22,643,935.31 Net cash received from disposal of fixed assets, intangible assets and other long-term assets 427,817.93 537,887.38 Other cash receipts relating to investing activities 56 - 54,984.60 Total cash inflows from investing activities 70,807,817.93 26,234,249.02 The accompanying notes form an integral part of these financial statementsCHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. CONSOLIDATED CASH FLOW STATEMENT (Continued) For the six months ended 30 June 2022 (Expressed in Renminbi Yuan) For the six months ended For the six months Note V 30 June 2022 ended 30 June 2021 2.CASH FLOWS FROM INVESTING ACTIVITIES (Continued) Cash payments to acquire fixed assets, intangible assets and other long-term assets 145,135,483.28 145,820,319.98 Cash payments for investments 41,189,363.04 70,724,113.00 Net cash payments for acquisition of subsidiaries - 100,950,637.41 and other business units Total cash outflows from investing activities 186,324,846.32 317,495,070.39 Net cash flows from investing activities (115,517,028.39) (291,260,821.37) 3.CASH FLOWS FROM FINANCING ACTIVITIES Cash proceeds from investments by others 2,700,000.00 15,680,000.00 Incl: Cash receipts from capital contributions from non-controlling interests of subsidiaries 2,700,000.00 15,680,000.00 Cash receipts from borrowings 1,241,724,044.08 915,684,894.52 Other cash receipts relating to financing activities 56 471,834,276.96 104,090,555.62 Total cash inflows from financing activities 1,716,258,321.04 1,035,455,450.14 Cash repayments for debts 965,274,913.52 511,076,477.58 Cash payments for distribution of dividends or profit and interest expenses 420,470,285.22 492,345,229.08 Incl: Dividends or profit paid to non-controlling shareholders of subsidiaries 32,667,189.54 22,846,959.82 Other cash payments relating to financing 56 710,226,995.71 838,045,248.87 activities Total cash outflows from financing activities 2,095,972,194.45 1,841,466,955.53 Net cash flows from financing activities (379,713,873.41) (806,011,505.39) The accompanying notes form an integral part of these financial statementsCHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. CONSOLIDATED CASH FLOW STATEMENT (Continued) For the six months ended 30 June 2021 (Expressed in Renminbi Yuan) For the six months For the six months Note V ended 30 June 2022 ended 30 June 2021 4.EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS (1,195,457.09) 392,002.63 5.NET INCREASE/ DECREASE IN CASH AND CASH 57 545,237,700.28 132,492,959.44 EQUIVALENTS Add: Cash and cash equivalents at beginning of the year 4,733,512,222.35 5,405,113,257.99 6.CASH AND CASH EQUIVALENTS AT END OF YEAR 57 5,278,749,922.63 5,537,606,217.43 The accompanying notes form an integral part of these financial statements CHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. COMPANY BALANCE SHEET As at 30 June 2022 (Expressed in Renminbi Yuan) ASSETS Note XIV 30 June 2022 31 December 2021 Current assets Cash and bank balances 3,662,982,819.92 3,098,512,437.04 Notes receivable 21,616,001.28 12,015,516.75 Accounts receivable 1 548,802,561.84 592,400,308.87 Receivables financing 5,928,782.68 - Advances to suppliers 4,017,222.47 11,762,344.40 Other receivables 2 4,612,252,981.71 5,003,805,208.01 Inventories 190,502,982.26 226,490,178.26 Contract Assets 180,503.66 139,021.45 Other current assets 39,482.38 39,482.38 Total current assets 9,046,323,338.20 8,945,164,497.16 Non-current assets Long-term equity investments 3 8,058,344,778.15 8,044,896,142.86 Other non-current financial assets 135,974,908.51 135,974,908.51 Investment properties 948,332.68 951,035.32 Fixed assets 13,407,637.52 12,824,750.51 Right-of-use assets 3,448,407.64 4,010,087.19 Intangible assets 5,247,419.44 5,682,864.94 Long-term prepaid expenses 5,593,368.23 6,438,007.85 Deferred tax assets 10,284,646.53 10,017,097.43 Other non-current assets 46,221,235.75 26,652,335.10 Total non-current assets 8,279,470,734.45 8,247,447,229.71 Total assets 17,325,794,072.65 17,192,611,726.87 The accompanying notes form an integral part of these financial statements CHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. COMPANY BALANCE SHEET (Continued) As at 30 June 2022 (Expressed in Renminbi Yuan) LIABILITIES AND SHAREHOLDERS’ 30 June 2022 31 December 2021 EQUITY Current liabilities Short-term borrowings 633,314,095.64 555,138,734.59 Notes payable 472,816,227.54 596,268,853.45 Accounts payable 467,416,626.20 480,059,192.74 Contract liabilities 5,491,416.33 3,231,968.16 Employee benefits payable 33,160,269.44 36,339,296.20 Tax payables 16,372,068.06 14,768,716.45 Other payables 3,902,656,317.48 3,832,642,249.25 Non-current liabilities due within one year 1,194,517.59 1,112,137.32 Other current liabilities 993,932.14 837,570.27 Total current liabilities 5,533,415,470.42 5,520,398,718.43 Non-current liabilities Long-term borrowings 31,633,794.44 31,637,173.89 Lease liabilities 2,715,432.43 3,343,830.66 Long-term payables 800,000.00 800,000.00 Deferred income 252,812.52 392,720.10 Other non-current liabilities 40,499,324.62 26,986,064.76 Total non-current liabilities 75,901,364.01 63,159,789.41 Total liabilities 5,609,316,834.43 5,583,558,507.84 The accompanying notes form an integral part of these financial statements CHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. COMPANY BALANCE SHEET (Continued) As at 30 June 2022 (Expressed in Renminbi Yuan) LIABILITIES AND SHAREHOLDERS’ 30 June 2022 31 December 2021 EQUITY Shareholders’ equity Share capital 428,126,983.00 428,126,983.00 Capital surplus 4,467,310,688.08 4,467,289,485.30 Other comprehensive income （90,613.57） （86,840.40） Surplus reserve 214,063,491.50 214,063,491.50 Retained earnings 6,607,066,689.21 6,499,660,099.63 Total shareholders’ equity 11,716,477,238.22 11,609,053,219.03 Total liabilities and shareholders’ equity 17,192,611,726.87 17,325,794,072.65 The accompanying notes form an integral part of these financial statementsCHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. COMPANY INCOME STATEMENT For the six months ended 30 June 2022 (Expressed in Renminbi Yuan) For the six months For the six months Note XIV ended 30 June 2022 ended 30 June 2021 Operating revenue 4 1,980,514,298.33 2,078,370,123.36 Less: Operating costs 4 1,910,062,248.84 1,991,420,311.80 Taxes and surcharges 2,313,767.23 2,488,284.74 Selling expenses 23,051,891.99 35,959,501.73 Administrative expenses 47,471,017.05 46,619,035.09 Finance costs (63,606,725.90) (55,486,414.78) Incl: Interest expense 29,325,391.91 27,864,903.28 Interest income 94,834,264.79 83,409,776.86 Add: Other incomes 610,612.91 1,931,159.58 Investment income 5 317,124,556.93 780,364,601.71 Incl: Investment income from associates 100,525,425.88 157,696,473.52 Income from the derecognition of financial assets measured at amortised cost (1,781,142.79) (221,815.32) Credit impairment losses 702,918.95 (123,032.41) Impairment losses (1,174,444.77) (281,770.77) Gain on disposal of assets 68,293.81 80,996.38 Operating profits 378,554,036.95 839,341,359.27 Add: Non-operating income 5,834.26 408,885.12 Less: Non-operating expenses 138,036.55 - Total profit 378,421,834.66 839,750,244.39 Less: Income tax expenses 14,139,055.28 15,144,476.73 Net profit 364,282,779.38 824,605,767.66 Profit or loss from continuing operations 364,282,779.38 824,605,767.66 Other comprehensive income, net of tax (3,773.17) 64,854.90 Other comprehensive income that will be reclassified to profit or loss (3,773.17) 64,854.90 Other comprehensive income using the equity method that will be reclassified to profit or loss (3,773.17) 64,854.90 Total comprehensive income 364,279,006.21 824,670,622.56 The accompanying notes form an integral part of these financial statementsCHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. COMPANY STATEMENT OF CHANGES IN EQUITY For the six months ended 30 June 2022 (Expressed in Renminbi Yuan) Other comprehensive For the six months ended 30 June 2022 Share capital Capital surplus Surplus reserve Retained earnings Total equity income I. Balance at end of prior year 428,126,983.00 4,467,289,485.30 (86,840.40) 214,063,491.50 6,499,660,099.63 11,609,053,219.03 II. Changes for the year - 21,202.78 (3,773.17) - 107,406,589.58 107,424,019.19 (1) Total comprehensive income - - (3,773.17) - 364,282,779.38 364,279,006.21 (2) Owners’ contributions and reduction in capital - 21,202.78 - - - 21,202.78 1.Others - 21,202.78 - - - 21,202.78 (3) Profit distribution - - - - (256,876,189.80) (256,876,189.80) 1. Distribution to owners - - - - (256,876,189.80) (256,876,189.80) III. Balance at end of year 428,126,983.00 4,467,310,688.08 (90,613.57) 214,063,491.50 6,607,066,689.21 11,716,477,238.22 The accompanying notes form an integral part of these financial statementsCHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. COMPANY STATEMENT OF CHANGES IN EQUITY (Continued) For the six months ended 30 June 2022 (Expressed in Renminbi Yuan) Other comprehensive For the six months ended 30 June 2021 Share capital Capital surplus Surplus reserve Retained earnings Total equity income I. Balance at end of prior year 428,126,983.00 4,467,991,431.59 (128,033.32) 214,063,491.50 5,788,050,243.66 10,898,104,116.43 II. Changes for the year - (460,868.29) 64,854.90 - 482,104,181.26 481,708,167.87 (1) Total comprehensive income - - 64,854.90 - 824,605,767.66 824,670,622.56 (2) Owners’ contributions and reduction in capital - (460,868.29) - - - (460,868.29) 1.Others - (460,868.29) - - - (460,868.29) (3) Profit distribution - - - - (342,501,586.40) (342,501,586.40) 1. Distribution to owners - - - - (342,501,586.40) (342,501,586.40) III. Balance at end of year 428,126,983.00 4,467,530,563.30 (63,178.42) 214,063,491.50 6,270,154,424.92 11,379,812,284.30 The accompanying notes form an integral part of these financial statementsCHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. COMPANY CASH FLOW STATEMENT For the six months ended 30 June 2022 (Expressed in Renminbi Yuan) For the six months For the six months ended 30 June 2022 ended 30 June 2021 1.CASH FLOWS FROM OPERATING ACTIVITIES Cash received from sales of good and the rendering of services 2,175,090,561.10 2,051,451,080.04 Other cash receipts relating to operating activities 26,226,243.98 31,548,087.03 Total cash inflows from operating activities 2,201,316,805.08 2,082,999,167.07 Cash payments for goods and services 2,062,445,434.60 1,882,952,590.62 Cash payments to and on behalf of employees 59,034,810.39 61,431,053.37 Payments of all types of taxes and surcharges 33,509,806.69 36,319,473.82 Other cash payments relating to operating 9,051,195.66 11,443,446.22 activities Total cash outflows from operating activities 2,164,041,247.34 1,992,146,564.03 Net cash flows from operating activities 37,275,557.74 90,852,603.04 2. CASH FLOWS FROM INVESTING ACTIVITIES Cash receipts from returns of investments - 2,997,441.73 Cash receipts from returns on investments 135,273,790.51 214,065,210.12 Net cash received from disposal of fixed assets, intangible assets and other long-term assets 119,999.00 339,163.00 Other cash receipts relating to investing activities 1,658,673,796.47 2,324,825,373.52 Total cash inflows from investing activities 1,794,067,585.98 2,542,227,188.37 Cash payments for acquisition of fixed assets, intangible assets and other long-term assets 1,961,637.93 2,302,398.23 Other cash payments relating to investing 1,172,734,389.30 2,155,040,000.00 activities Total cash outflows from investing activities 1,174,696,027.23 2,157,342,398.23 Net cash flows from investing activities 619,371,558.75 384,884,790.14 The accompanying notes form an integral part of these financial statementsCHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. COMPANY CASH FLOW STATEMENT (Continued) For the six months ended 30 June 2022 (Expressed in Renminbi Yuan) For the six months For the six months ended 30 June 2022 ended 30 June 2021 3. CASH FLOWS FROM FINANCING ACTIVITIES Cash receipts from borrowings 253,374,494.30 280,000,000.00 Other cash receipts relating to financing activities 25,607,545,958.40 18,653,623,031.33 Total cash inflows from financing activities 25,860,920,452.70 18,933,623,031.33 Cash repayments for debts 280,000,000.00 30,164,821.52 Cash payments for distribution of dividends or profit and interest expenses 283,891,846.04 363,151,913.01 Other cash receipts relating to financing activities 25,388,009,883.18 18,673,121,608.99 Total cash outflows from financing activities 25,951,901,729.22 19,066,438,343.52 Net cash flows from financing activities (90,981,276.52) (132,815,312.19) 4.EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS (1,195,457.09) 392,002.63 5. NET INCREASE IN CASH AND CASH EQUIVALENTS 564,470,382.88 343,314,083.62 Add: Cash and cash equivalents at beginning of 3,098,512,437.04 3,020,909,473.71 the year 6. CASH AND CASH EQUIVALENTS 3,662,982,819.92 3,364,223,557.33 AT END OF YEAR The accompanying notes form an integral part of these financial statements CHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. Notes to financial statements For the six months ended 30 June 2022 (All amounts in Renminbi “RMB” unless otherwise stated) I Profile of the Company (1) Historical development and basic information As approved by the People’s Government of Shenzhen (SFBF (1993) No.356), China National Accord Medicines Corporation Ltd. (hereinafter referred to as the “the Company”), formerly known as Shenzhen Health Mineral Water Corp., Ltd., was registered as a joint stock liability limited company on 1 February 1993 through stock transformation. In March 1993, with the approval from the Shenzhen Branch of the People’s Bank of China, the Company issued 30 million A shares (including 16.50 million public shares, 3.50 million employee shares and 10 million corporation shares) and 20 million B shares. After this issuance, the Company’s share capital was RMB105 million. Through convert capital surplus into share capital, bonus issues and issuance of shares for years, the share capital of the Company increased to RMB428.13 million as at 30 June 2022 In November 2000, the Company entered into an Assets Exchange Agreement with Shenzhen Investment Management Company, the original major shareholder of the Company, to exchange all the assets and liabilities of the Company as of 31 August 2000 for Shenzhen Investment Management Company’s 100% equity interests in 11 pharmaceutical companies and certain properties as well as 51% equity interests in Shenzhen Tefa Modern Computer Co., Ltd. The above asset exchange proposal was approved by shareholders in the Second Extraordinary General Meeting on December 29, 2000. The transaction was completed on 8 January 2001. On 18 February 2004, the Company’s original major shareholder, Shenzhen Investment Management Company, entered into a Stock Transfer Agreement with Sinopharm Group Co., Ltd. (hereinafter referred to as “Sinopharm Group”) to transfer its 43.33% shares in the Company to Sinopharm Group. The legal procedures of the above equity transfer were completed on 9 December 2004. At the same time, as approved by the State-owned Assets Supervision and Administration Commission of the State Council (GZCQ (2004) No.525) and the China Securities Regulatory Commission (ZJGSZ (2004) No.94), the nature of these shares was changed from state-owned stock to state-owned legal entity stock and Sinopharm Group became the largest shareholder of the Company. On 14 April 2006, the Company’s proposal on reformation of segregated stocks was approved. To gain liquidity for the restricted stocks of the Company, the holders of the restricted stocks of the Company agreed to pay the following consideration: based on the stock registration as of 27 April 2006, the Company issued bonus shares on 28 April 2006 at the ratio of 3 shares to every 10 A shares to liquidated A-shareholders which went public on the same day. After this bonus issue, the total number of shares of the Company remained unchanged with corresponding changes in the composition of shareholdings. On March 14 2014, the company issued 74,482,543 ordinary shares (A shares) through the non-public offering. Par value per share is RMB1.00. The shares shall not be transferred within 36 months since the issue day. The total number of shares of the Company was 362,631,943 since the date of issue. CHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. Notes to financial statements For the six months ended 30 June 2022 (All amounts in Renminbi “RMB” unless otherwise stated) I Profile of the Company (Continued) (1) Historical development and basic information (Continued) The Company acquired the companies under common control, including Sinopharm Holding Guoda Drugstore Co., Ltd. (“Guoda Drugstore”), Foshan Nanhai Medicine Group Co., Ltd. (“Foshan Nanhai”), Guangdong South Pharmaceutical Foreign Trade Co., Ltd. (“South Pharma & Trade”) and Guangdong Dong Fang Uptodate & Special Medicines Co., Ltd. (“Guangdong Uptodate & Special Medicines”) by issuing shares and raised supporting funds by issuing shares to Ping An Asset Management Co., Ltd. to acquire the non-controlling interest of South Pharma & Trade. The above transactions were completed on 31 December 2016, and the relevant shares were successfully issued and listed on 5 January 2017. Afterwards, the total number of shares of the Company increased to 428,126,983. As of 30 June 2022, the total share capital was RMB428.13 million. The Company is registered with Shenzhen Administration for Industry & Commerce. Its Uniform Social Credit Code is 91440300192186267U. The operation period of the Company is from 2 August 1986 to the long term. The registered capital of the Company is RMB428.13 million. The legal representative of the Company is Lin Zhaoxiong. The approved scope of business of the Company and its subsidiaries (together “the Group”) includes: the wholesale of traditional Chinese medicine preparations, bulk pharmaceutical drugs, chemical preparations, bulk antibiotic drugs, antibiotic preparations, biochemical drugs, biological products (including vaccines and in vitro diagnostic reagents psychotropic drugs and preparations, narcotic drugs, toxic drugs for medical use, protein assimilation preparation and peptide hormones; trading of dietary supplement; research, development and consultation services of pharmaceutical packaging materials and pharmaceutical industry products; industrial investment holding; domestic trade; material supply and marketing industry (other than special licensing); sale of ambulances; trade of second-class and third- class medical equipment; project investment; property management and leasing of self-owned properties; pharmacovigilance and medical information consulting; parking operation; logistics and related services; package agency business; logistic design; import and export services (excluding projects that are prohibited by the country; and limited projects has to be approved before operating). CHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. Notes to financial statements For the six months ended 30 June 2022 (All amounts in Renminbi “RMB” unless otherwise stated) I Profile of the Company (Continued) (2) The Group’s parent and ultimate parent companies are Sinopharm Group and China National Pharmaceutical Group Corporation (“CNPGC”) , respectively. (3) These financial statements were authorized for issue by the board of directors of the Company on 30 August 2022. (4) Subsidiaries consolidated in the financial statements for the current period and change in the consolidation scope are shown in Note VI. II Basis of preparation The financial statements were prepared in accordance with the Basic Standard and specific standards of Accounting Standards for Business Enterprises issued by the Ministry of Finance and the specific accounting standards, application guidance, interpretation and other relevant regulations issued or amended thereafter (hereafter collectively referred to as “Accounting Standards for Business Enterprises” or “CAS”). These financial statements are prepared on a going concern basis. Except for certain financial instruments, the financial statements have been prepared using the historical cost as the principle of measurement. Where assets are impaired, provisions for asset impairment are made in accordance with the relevant requirements. CHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. Notes to financial statements For the six months ended 30 June 2022 (All amounts in Renminbi “RMB” unless otherwise stated) III Summary of significant accounting policies and accounting estimates The Group determines the specific accounting policies and estimates based on its features of production and operation, primarily comprising the methods of provision for expected credit losses on receivables, valuation of inventories, depreciation of fixed assets and amortisation of intangible assets, the measurement model of investment properties, recognition and measurement of revenue, etc. (1) Statement of compliance with the Accounting Standards for Business Enterprises The financial statements of the Company for the year ended 30 June 2022 are in compliance with Accounting Standards for Business Enterprises, and truly and completely present the financial position of the Group and the Company as of 30 June 2022 and the operating results, cash flows and other information for the six months ended 30 June 2022 of the Group and the Company. (2) Accounting year The Company’s accounting year begins on 1 January and ends on 31 December. (3) Business cycle The Company’s operating cycle is 12 months. (4) Functional currency The Group’s functional and presentation currency is Renminbi (RMB). The currency unit is RMB Yuan unless otherwise stated. (5) Business combinations Business combinations are classified into business combinations involving enterprises under common control and business combinations not involving enterprises under common control. (a) Business combinations involving enterprises under common control A business combination involving enterprises under common control is a business combination in which all of the combining enterprises are ultimately controlled by the same party or parties both before and after the combination, and that control is not transitory. In a business combination involving enterprises under common control, the enterprise that, at the combination date, obtains control of another combining enterprise is the absorbing enterprise, while that other combining enterprise is the enterprise being absorbed. The combination date is the date on which the absorbing enterprise effectively obtains control on the enterprise being absorbed. The assets and liabilities (including goodwill arising from the ultimate controlling party’s acquisition of the enterprise being absorbed) that are obtained by the absorbing enterprise in a business combination involving enterprises under common control shall be measured on the basis of their carrying amounts in the financial statements of the ultimate controlling party at the combination date. The difference between the carrying amount of the net assets obtained and the carrying amount of the consideration paid for the combination (or the aggregate face value of shares issued as consideration) shall be adjusted to capital premium under capital reserves and the balance transferred from capital reserves CHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. Notes to financial statements For the six months ended 30 June 2022 (All amounts in Renminbi “RMB” unless otherwise stated) III Summary of significant accounting policies and accounting estimates (Continued) (5) Business combinations (Continued) (b) Business combinations involving enterprises not under common control A business combination not involving enterprises under common control is a business combination in which all of the combining enterprises are not ultimately controlled by the same party or parties both before and after the combination. In a business combination not involving enterprises under common control, the enterprise that, on the acquisition date, obtains control of another combining enterprise is the acquirer, while that other combining enterprise is the acquiree. The acquisition date is the date on which the acquirer effectively obtains control of the acquiree. The acquirer shall measure the acquiree’s identifiable assets, liabilities and contingent liabilities acquired in the business combination at their fair values on the acquisition date. Goodwill is initially recognised and measured at cost, being the excess of the aggregate of the fair value of the consideration transferred (or the fair value of the equity securities issued) and any fair value of the Group’s previously held equity interest in the acquiree over the Group’s interest in the fair value of the acquiree’s net identifiable assets. After initial recognition, goodwill is measured at cost less any accumulated impairment losses. Where the aggregate of the fair value of the consideration transferred (or the fair value of the equity securities issued) and any fair value of the Group’s previously held equity interest in the acquiree is lower than the Group’s interest in the fair value of the acquiree’s net identifiable assets, the Group reassesses the measurement of the fair value of the acquiree’s identifiable assets, liabilities and contingent liabilities and the fair value of the consideration transferred (or the fair value of the equity securities issued), together with the fair value of the Group’s previously held equity interest in the acquiree. If after that reassessment, the aggregate of the fair value of the consideration transferred (or the fair value of the equity securities issued) and the Group’s previously held equity interest in the acquiree is still lower than the Group’s interest in the fair value of the acquiree’s net identifiable assets, the Group recognises the remaining difference in profit or loss. Where the business combination not involving enterprises under common control is achieved in stages, the acquirer’s previously held equity interests in the acquiree are remeasured at the fair value on the acquisition date, with the difference between the fair value and carrying amount recognised as investment income for the current period. If the acquirer’s previously held equity interests of the acquiree involve other comprehensive income (“OCI”) under the equity method, the accounting treatment is conducted on the same basis as would have been required if the investee had directly disposed of the related assets or liabilities, and the changes in shareholders’ equity other than net profit or loss, OCI and profit distributions are charged to profit or loss for the current period on the acquisition date. For financial assets at fair value through OCI held before the acquisition date, changes in fair value that were accumulated through OCI will transfer to retained earnings. （未完）  |